Louisiana State Employees Retirement System purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,200 shares of the life sciences company's stock, valued at approximately $3,091,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its stake in shares of Illumina by 15.0% in the 3rd quarter. Vanguard Group Inc. now owns 17,967,758 shares of the life sciences company's stock valued at $2,466,614,000 after buying an additional 2,336,935 shares in the last quarter. Polen Capital Management LLC raised its holdings in Illumina by 0.6% during the third quarter. Polen Capital Management LLC now owns 5,126,614 shares of the life sciences company's stock valued at $703,782,000 after buying an additional 29,153 shares in the last quarter. Loomis Sayles & Co. L P lifted its position in shares of Illumina by 5.5% in the third quarter. Loomis Sayles & Co. L P now owns 4,007,957 shares of the life sciences company's stock worth $550,212,000 after buying an additional 208,267 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Illumina by 6.6% during the 3rd quarter. Bank of New York Mellon Corp now owns 3,648,935 shares of the life sciences company's stock worth $500,926,000 after acquiring an additional 225,074 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Illumina by 1.9% during the 1st quarter. Geode Capital Management LLC now owns 2,928,326 shares of the life sciences company's stock valued at $679,269,000 after acquiring an additional 54,951 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on ILMN. Barclays upped their target price on Illumina from $85.00 to $100.00 and gave the stock an "underweight" rating in a research report on Wednesday, April 10th. HSBC lowered shares of Illumina from a "buy" rating to a "hold" rating in a research note on Tuesday, January 16th. TD Cowen lowered shares of Illumina from an "outperform" rating to a "market perform" rating and set a $144.00 target price for the company. in a research report on Thursday, January 4th. StockNews.com raised Illumina from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Finally, OTR Global reiterated a "mixed" rating on shares of Illumina in a research note on Wednesday, March 20th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Hold" and an average price target of $167.70.
Read Our Latest Stock Report on ILMN
Illumina Stock Down 2.9 %
Shares of Illumina stock traded down $3.47 during trading on Tuesday, hitting $117.69. 1,698,190 shares of the company's stock traded hands, compared to its average volume of 1,761,661. Illumina, Inc. has a twelve month low of $89.00 and a twelve month high of $232.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.66 and a quick ratio of 1.29. The firm's fifty day moving average price is $135.35 and its 200 day moving average price is $128.35.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings data on Thursday, February 8th. The life sciences company reported $0.14 earnings per share for the quarter, beating analysts' consensus estimates of $0.01 by $0.13. Illumina had a positive return on equity of 2.20% and a negative net margin of 25.78%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the business earned $0.14 earnings per share. The company's quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current fiscal year.
Insider Buying and Selling at Illumina
In related news, CEO Jacob Thaysen acquired 7,330 shares of the business's stock in a transaction on Thursday, February 22nd. The stock was bought at an average cost of $135.29 per share, with a total value of $991,675.70. Following the completion of the acquisition, the chief executive officer now owns 14,861 shares in the company, valued at $2,010,544.69. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 0.17% of the company's stock.
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Featured Articles
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
